Effect of Magnesium Sulphate on Neostigmine

Effect of Magnesium Sulphate on Neostigmine-induced Reversal of Neuromuscular Block by Rocuronium

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03020706

Enrollment

166

Registered

2017-01-13

Start date

2016-12-31

Completion date

2017-12-31

Last updated

2017-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Blockade

Keywords

magnesium sulphate, neostigmine

Brief summary

The purpose of this study is to evaluate the effect of magnesium sulphate on neostigmine-induced reversal of neuromuscular block by rocuronium

Detailed description

Comparison of reversa time by neostigmine in magnesium group and control group

Interventions

DRUGMagnesium Sulfate, Injectable

magnesium sulphate intravenous administration during general anesthesia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* ASA status 1 or 2 * patients undergoing surgery for more than 60 min under general anesthesia

Exclusion criteria

* electrolyte abnormalities * medication on aminoglycoside, antiepileptic drug, magnesium * underweight or obesity (BMI \<18.5 or \>30) * renal insufficiency (Cr\>1.4 mg/dl) * AV block * neuromuscular disease (ex: Myathenia gravis)

Design outcomes

Primary

Measure	Time frame	Description
reversal time	through study completion, an average of 90 minutes	reversal time: from neostigmine injection to TOF ratio 0.9

Countries

South Korea

Contacts

Primary ContactHee-Yeon Park, MD

hypark@gilhospital.com+82 10 3360 0790

Backup ContactSang-Hwan Do, MD, Ph D

shdo@snu.ac.kr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026